{"id":50346,"date":"2022-06-27T12:50:39","date_gmt":"2022-06-27T11:50:39","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=50346"},"modified":"2023-05-25T21:40:15","modified_gmt":"2023-05-25T20:40:15","slug":"benjamin-weingberg-asco-2022-highlights-of-asco-in-colorectal-cancer","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/benjamin-weingberg-asco-2022-highlights-of-asco-in-colorectal-cancer\/","title":{"rendered":"Benjamin Weinberg, ASCO 2022: Highlights of ASCO in colorectal cancer, the PARADIGM study"},"content":{"rendered":"
PARADIGM is the first prospective trial to examine panitumumab versus bevacizumab in colorectal cancer. Professor Benjamin Weinberg <\/b>(Georgetown University, Washington, DC, USA) discusses the findings of the phase III PARADIGM study in patients with RAS wild-type (WT) metastatic colorectal cancer.<\/p>\n
The abstract entitled \u2018Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial’\u00a0(Abstract number\u00a0LBA10<\/a>) was presented at the ASCO<\/a>\u00a0annual meeting,\u00a0June 3-7, 2022.<\/p>\n Disclosures<\/strong>: Benjamin Weinberg has received grant\/research support from Ipsen, is on the advisory board for Bayer and Taiho and the speaker\u2019s bureau for AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Sirtex and Taiho.<\/p>\n Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/p>\n